Background Efficacious vaccines are urgently needed to contain the ongoing coronavirus
disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome …

The Ad26.COV2.S vaccine 1 , 2 – 3 has demonstrated clinical efficacy against symptomatic
COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing …

Human immunodeficiency virus type 1 (HIV-1)-specific monoclonal antibodies with extraordinary
potency and breadth have recently been described. In humanized mice, combinations …

Importance Control of the global COVID-19 pandemic will require the development and
deployment of safe and effective vaccines. Objective To evaluate the immunogenicity of the Ad26…

Durability of Response after Ad26.COV2.S Vaccination In this study, investigators measured
immune responses in 20 participants who had received either one or two doses of the Ad26.…

Zika virus (ZIKV) is responsible for a major ongoing epidemic in the Americas and has been
causally associated with fetal microcephaly. The development of a safe and effective ZIKV …

Chikungunya virus is widespread throughout the tropics, where it causes recurrent outbreaks
of chikungunya fever. In recent years, outbreaks have afflicted populations in East and …

The COVID-19 pandemic has led to extensive morbidity and mortality throughout the world.
Clinical features that drive SARS-CoV-2 pathogenesis in humans include inflammation and …

The global diversity of HIV-1 represents a critical challenge facing HIV-1 vaccine development.
HIV-1 mosaic antigens are bioinformatically optimized immunogens designed for …

Background More than 1·8 million new cases of HIV-1 infection were diagnosed worldwide
in 2016. No licensed prophylactic HIV-1 vaccine exists. A major limitation to date has been …